Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

|Videos|December 22, 2022

Available Adjuvant Therapy Options for Patients with Stage II or III MIBC After Previous Cystectomy

Author(s)Karim Chamie, MD

Karim Chamie, MD, reviews the currently available adjuvant therapy options for patients with stage II or III MIBC who received a cystectomy, and whether he would have treated the patient in the presented case or referred her to a medical oncologist.

Episodes in this series

EP. 1 Case 1 Presentation: A 60-Year-Old Woman With Muscle-Invasive Bladder Cancer (MIBC)

EP. 1 Case 1 Presentation: A 60-Year-Old Woman With Muscle-Invasive Bladder Cancer (MIBC)

EP. 2 Determining Cisplatin Eligibility for Patients with MIBC

EP. 2 Determining Cisplatin Eligibility for Patients with MIBC

EP. 3 Available Adjuvant Therapy Options for Patients with Stage II or III MIBC After Previous Cystectomy

EP. 3 Available Adjuvant Therapy Options for Patients with Stage II or III MIBC After Previous Cystectomy

EP. 4 Communication and Follow-Up Strategies After Referring a Patient with MIBC to Medical Oncology

EP. 4 Communication and Follow-Up Strategies After Referring a Patient with MIBC to Medical Oncology

EP. 5 Case 2 Presentation: A 77-Year-Old Man With MIBC

EP. 5 Case 2 Presentation: A 77-Year-Old Man With MIBC

EP. 6 Unmet Needs and Clinical Challenges in the Management of MIBC

EP. 6 Unmet Needs and Clinical Challenges in the Management of MIBC

EP. 7 Potential Future Approaches to Neoadjuvant and Adjuvant Immunotherapy for MIBC

EP. 7 Potential Future Approaches to Neoadjuvant and Adjuvant Immunotherapy for MIBC

EP. 8 Clinical Pearls for Community Urologists Treating Patients with MIBC

EP. 8 Clinical Pearls for Community Urologists Treating Patients with MIBC

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Christopher Filson, MD, on using CxBladder Triage to risk-align cystoscopy in microhematuria

ByChristopher P. Filson, MD, MS

February 9th 2026

Sarah Azari, MD, on early sexual health education for women with bladder cancer

BySarah Azari, MD

February 6th 2026

FDA premarket approval sought for Signatera CDx test in MIBC

ByHannah Clarke

February 2nd 2026

Kristen Scarpato, MD, on combination strategies in BCG-naïve NMIBC

ByKristen R. Scarpato, MD, MPH

January 31st 2026

John Sfakianos, MD, on dual immune checkpoint inhibition in NMIBC

ByJohn P. Sfakianos, MD

January 29th 2026

Latest CME

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

February 23, 2026

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

Trending on Urology Times

FDA approves sildenafil oral film for men with erectile dysfunction

Pearls & Perspectives: Prioritizing Sexual Health After Spinal Cord Injury, with Emad Ibrahim, MD, HCLD

Kalyani Narra, MD, discusses overcoming barriers to genetic counseling in safety-net care

Christopher Filson, MD, on using CxBladder Triage to risk-align cystoscopy in microhematuria

The UroOnc Minute: Adjuvant Therapy in Renal Cell Carcinoma, with Brian Shuch, MD